Cidara Therapeutics, Inc.
CDTX
Clasificación en acciones
#3183
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Precio por acción
$221.38
Última sincronización: 2026-01-08
Capitalización bursátil
$5.61B
Cambio (1 día)
0.00%
Cambio (1 año)
118.07%
País
US
Comercio Cidara Therapeutics, Inc. (CDTX)
Categoría
Healthcare
EPS de Cidara Therapeutics, Inc. (CDTX)
EPS a fecha de September 2025 TTM: $-11.78
Según los últimos informes financieros y el precio de las acciones de Cidara Therapeutics, Inc., el EPS actual de la empresa (TTM) es $-11.78. Al final del año 2023, la empresa tenía un EPS de $-5.25 una disminución en comparación con al EPS de 2022, que fue de $-9.61.
Historial de EPS de Cidara Therapeutics, Inc. desde 2012 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-11.78 | -55.96% |
| 2024 | $-26.75 | 409.52% |
| 2023 | $-5.25 | -45.37% |
| 2022 | $-9.61 | -40.68% |
| 2021 | $-16.20 | -55.04% |
| 2020 | $-36.03 | 34.54% |
| 2019 | $-26.78 | -41.30% |
| 2018 | $-45.62 | -28.37% |
| 2017 | $-63.69 | -4.21% |
| 2016 | $-66.49 | 42.19% |
| 2015 | $-46.76 | -83.88% |
| 2014 | $-290.15 | 249.41% |
| 2013 | $-83.04 | 85.77% |
| 2012 | $-44.70 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -247.03% |
US
|
|
| $-7.98 | -32.26% |
US
|
|
| $-5.29 | -55.09% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -335.48% |
NL
|
